Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer

26 Jan 2017

Abstract excerpt

Detection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1 mfcDNA in mCRC patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1 mfcDNA is a suitable prognostic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28124380
DOI: 10.1002/ijc.30625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancerPMID 28124380Read ↗

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.Semantic proximity Read ↗

Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and SequencingSemantic proximity Read ↗

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).Semantic proximity Read ↗

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful WaitingSemantic proximity Read ↗

Hypermethylated DNA, a circulating biomarker for colorectal cancer detectionSemantic proximity Read ↗

Prognostic role of methylated free circulating DNA in colorectal cancerSemantic proximity Read ↗

Plasma clearance ofRASmutation under therapeutic pressure is a rare event in metastatic colorectal cancerSemantic proximity Read ↗

Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancerSemantic proximity Read ↗

Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosisSemantic proximity Read ↗

Aberrant promoter methylation of <i>PPP1R3C</i> and <i>EFHD1</i> in plasma of colorectal cancer patientsSemantic proximity Read ↗

Methylation status and long‐fragment cell‐free DNA are prognostic biomarkers for gastric cancerSemantic proximity Read ↗

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.